Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00742027. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkins Lymphoma After High-dose Chemotherapy With Autologous Stem Cell Transplant
Study identification
- NCT ID
- NCT00742027
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Interventions
- Panobinostat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2008
- Primary completion
- Aug 11, 2013
- Completion
- Aug 11, 2013
- Last update posted
- Jul 27, 2021
2008 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(2) | Duarte | California | 91010-3000 | — |
| Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) | Atlanta | Georgia | 30322 | — |
| Georgia Regents University Cancer Clinical Research Unit | Augusta | Georgia | 30912 | — |
| Rush University Medical Center Divisionof Hem/Onc Research(2) | Chicago | Illinois | 60612 | — |
| VA Maryland Health Care Dept.of GreenbaumCancerCent(5) | Baltimore | Maryland | 21201 | — |
| Dana Farber Cancer Institute Hematology / Oncology | Boston | Massachusetts | 02115 | — |
| Karmanos Cancer Institute Div.of Hematology/Oncology | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Rochester Hematology | Rochester | Minnesota | 55905 | — |
| University of Pennsylvania Medical Center Dept of UPenn Med Ctr (3) | Philadelphia | Pennsylvania | 19104-4283 | — |
| University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3) | Houston | Texas | 77030-4009 | — |
| The Methodist Hospital Cell & Gene Therapy Clinic | Houston | Texas | 77030 | — |
| Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5) | San Antonio | Texas | 78229 | — |
| West Virginia University/ Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00742027, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2021 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00742027 live on ClinicalTrials.gov.